Rates of Symptomatic Intracranial Hemorrhage with Tenecteplase vs. with Alteplase

In a multicenter review, tenecteplase was associated with a lower rate of symptomatic brain hemorrhage.

Two recent clinical trials have demonstrated that outcomes following ischemic stroke treatment with tenecteplase versus with alteplase are comparable. To examine outcomes in routine clinical practice, these authors conducted a review of data from July 2018 through June 2021 at more than 100 hospitals in three countries that were using tenecteplase for acute stroke thrombolysis. The primary endpoint was the rate of symptomatic intracranial hemorrhage (sICH), defined as an intracranial hemorrhage with worsening of 4 or more points on the NIH stroke scale (NIHSS).

The 9238 included patients had a median age of 71 years, 48% were women, 21% received tenecteplase (most often 0.25 mg/kg), and 79% received alteplase. The patients who received tenec…

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Rates of Symptomatic Intracranial Hemorrhage with Tenecteplase vs. with Alteplase

Topics

Reviewing Author